Landos has filed to go public after a phase 2 trial of its Virginia Tech-invented IBD treatment produced favourable results this month.
Landos Biopharma, a US-based autoimmune disease therapeutics developer exploiting Virginia Tech research, has filed for a $100m initial public offering.
Founded in 2017, the spinout has been working on a small molecule-based drug called BT-11 to treat autoimmune and inflammatory problems associated with two forms of inflammatory bowel disease (IBD): Crohn’s disease and ulcerative colitis.
Earlier this month, an orally-administered form of the drug demonstrated positive effects in a 12-week phase 2 trial with patients suffering mild-to-moderate ulcerative colitis.
IBD symptoms were resolved or mostly alleviated in up to 11.5% of the trial’s participants, Landos said, and the drug was shown to be safe with tolerable side-effects.
A phase 3 trial is expected to follow in the first half of this year, along with a phase 2 trial indicated for Crohn’s disease.
Landos is also working toward initial in-human studies of BT-11 to establish…
